Agenus Inc. (NASDAQ:AGEN) shares rose 2.5% on Wednesday . The stock traded as high as $6.29 and last traded at $6.20, with a volume of 718,687 shares. The stock had previously closed at $6.05.

Several research firms have issued reports on AGEN. Maxim Group reissued a “buy” rating on shares of Agenus in a research note on Wednesday, April 27th. HC Wainwright reissued a “buy” rating on shares of Agenus in a research note on Saturday, April 30th. Jefferies Group lifted their price target on Agenus from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Finally, Zacks Investment Research raised Agenus from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $10.25.

The stock’s 50 day moving average price is $5.34 and its 200-day moving average price is $4.19. The company’s market cap is $508.44 million.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, July 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.01. The company had revenue of $6.59 million for the quarter, compared to the consensus estimate of $5.12 million. On average, analysts expect that Agenus Inc. will post ($1.27) EPS for the current year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.